MMSL 2024, 93(1):140-149 | DOI: 10.31482/mmsl.2023.002

GLUTAMATE AS A TARGET THERAPY FOR ALCOHOL DEPENDENCE DISORDERReview article

Safa Mustafa Najim1, Zainab Ahmed Sadeq2, Lubna A. Sabri ORCID...2*
1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq
2 Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq

Alcoholism (Alcohol dependence) is considered a serial health problem because of tendency for con-sumption more alcohol, control losing and the physical dependence development. This cycle in most often featured by periods of craving, abstinence, and relapse. The cholinergic, adrenergic, dopaminergic, glutamatergic, GABAergic, serotonergic, peptidergic, and different neurotransmitter systems in the brain are affected by alcohol consumption. The development of alcohol dependence is attributed to neuro-adaptations within the extended amygdala and mesocorticolimbic systems. Principally, the glutamatergic neurotransmission variations that resulted by alcohol consumption, lead to researches recommended in a focus on normalization of glutamatergic neurotransmission and glutamatergic receptors as a targeting therapy. Glutamatergic receptors are classified to ionotropic glutamate receptors (AMPA, Kainate, and NMDA) and metabotropic receptors. Sodium dependent excitatory amino acid transporters (EAATs) and vesicular glutamate transporters (VGLUTs). Additionally, cysteine-glutamate antiporter which regulates cysteine -glutamate exchange at the synapse. At least 90% of extracellular glutamate displace particularly by GLT1. Ceftriaxone, GPI-1046 and MS-153, upregulate expression of glutamate transporter 1 (GLT1) in mesocorticolimbic brain region.

Keywords: Alcohol dependence; Glutamate; GLT1; Pharmacotherapy

Received: September 8, 2022; Revised: January 5, 2023; Accepted: January 5, 2023; Prepublished online: February 21, 2023; Published: March 1, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Najim, S.M., Sadeq, Z.A., & Sabri, L.A. (2024). GLUTAMATE AS A TARGET THERAPY FOR ALCOHOL DEPENDENCE DISORDER. MMSL, 93(1), 140-149. doi: 10.31482/mmsl.2023.002
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Airapetov M, Eresko S, Lebedev A, et al. The role of Toll-like receptors in neurobiology of alcoholism. BioScience Trends. 2021;15(2):74-82. Go to original source... Go to PubMed...
    2. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. AMA. 2021;325(18):1829-1830. Go to original source... Go to PubMed...
    3. Manthey J, Hassan SA, Carr S, et al. What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study. PharmacoEconomics. 2021:39(7)809-822. Go to original source... Go to PubMed...
    4. Nadkarni A, Endsley P, Bhatia U, et al. Community detoxification for alcohol dependence: a systematic review. Drug and Alcohol Review. 2017;36(3):389-399. Go to original source... Go to PubMed...
    5. Sinclair JMA, O'Neill A. Update on the management of alcohol use disorders. BJPsych Advances .2020;26(2):82-91. Go to original source...
    6. Oreland L, Lagravinese G, Toffoletto S, et al. Personality as an intermediate phenotype for genetic dissection of alcohol use disorder. J Neural Transm.2018;125(1):107-130. Go to original source... Go to PubMed...
    7. Rubens M, Ramamoorthy V, Attonito J, et al. A review of 5-HT transporter linked promoter region (5-HTTLPR) polymorphism and associations with alcohol use problems and sexual risk behaviors. J Comm Genet. 2016;7(1):1-10. Go to original source... Go to PubMed...
    8. Gortney JS, JRaub JN, Patel P. Alcohol withdrawal syndrome in medical patients. Cleveland Clinic Journal of Medicine. 2016;83(1):67-79. Go to original source... Go to PubMed...
    9. Olivier George. Individual differences in the neuropsychopathology of addiction. Dialogues Clin Neurosci. 2017;19(3):217-229. Go to original source... Go to PubMed...
    10. Singh AK. Alcohol Interaction with Cocaine, Methamphetamine, Opioids, Nicotine, Cannabis, and γ-Hydroxybutyric Acid. Biomedicines 2019;7(1):16. Go to original source... Go to PubMed...
    11. LCarton L, Auger F, Kyheng M, et al. Dose-dependent metabolite changes after ethanol intoxication in rat prefrontal cortex using in vivo magnetic resonance spectroscopy. Scientific Reports. 2019;9:(10682):1-8. Go to original source... Go to PubMed...
    12. Tabakoff B, Hoffman PL. The neurobiology of alcohol consumption and alcoholism: an integrative history. Pharmacol. Biochem. Behav. 2013;113(15):20-37. Go to original source... Go to PubMed...
    13. Sarawagi A, Soni ND, Patel AB. Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder. Front Psychiatry 2021;27(12):6378. Go to original source... Go to PubMed...
    14. Volman SF, Lammel S, Margolis EB, et al. New insights into the specificity and plasticity of reward and aversion encoding in the mesolimbic system. J. Neurosci. 2013;33(45):17569-17576. Go to original source... Go to PubMed...
    15. Brooks AM, Berns GS. Aversive stimuli and loss in the mesocorticolimbic dopamine system. Trends in Cognitive Sciences. 2013;17(6):281-286. Go to original source... Go to PubMed...
    16. Babaev O, Chatain CP, Krueger-Burg D. Inhibition in the amygdala anxiety circuitry. Exp Mol Med. 2018;50(4):18. Go to original source... Go to PubMed...
    17. Alasmari F, Goodwani S, Robert E. et al. Role of glutamatergic system and mesocorticolimbic circuits in alcohol dependence. Prog Neurobiol. 2018;171:32-49. Go to original source... Go to PubMed...
    18. Rao PSS, Bell RL, Engleman EA, et al. Targeting glutamate uptake to treat alcohol use disorders. Front. Neurosci. 2015;9(144). Go to original source... Go to PubMed...
    19. Youn DH, Gerber G, Sather WA. Ionotropic glutamate receptors and voltage-gated Ca<sup>2</sup>⁺ channels in long-term potentiation of spinal dorsal horn synapses and pain hypersensitivity. Neural Plast. 2013;2013(654257). 19 pages. Go to original source...
    20. Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front. Mol. Neurosci.2019;12(20):1-11. Go to original source... Go to PubMed...
    21. Bell RL, Hauser SR, McClintick J, et al. Ethanol-Associated Changes in Glutamate Reward Neurocircuitry: A Minireview of Clinical and Preclinical Genetic Findings. Prog Mol Biol Transl Sci. 2016;137:41-85. Go to original source... Go to PubMed...
    22. Obara I, Bell RL, Goulding SP, et al. Differential effects of chronic ethanol consumption and withdrawal on homer/glutamate receptor expression in subregions of the accumbens and amygdala of P rats. Alcoholism: Clinical and Experimental Research. 2009;33(11):1924-34. Go to original source... Go to PubMed...
    23. Zhu W, Bie B, Pan ZZ. Involvement of non-NMDA glutamate receptors in central amygdala in synaptic actions of ethanol and ethanol-induced reward behavior. Journal of Neuroscience. 2007;27(2):289-98. Go to original source... Go to PubMed...
    24. Marszalek-Grabska M, Smaga I, Surowka P. Memantine Prevents the WIN 55,212-2 Evoked Cross-Priming of Ethanol-Induced Conditioned Place Preference (CPP). Int. J. Mol. Sci. 2021;22(15):7940. Go to original source... Go to PubMed...
    25. Trantham-Davidson H, Chandler LJ. Alcohol-induced alterations in dopamine modulation of prefrontal activity. Alcohol. 2015;49(8):773-779. Go to original source... Go to PubMed...
    26. Kirdajova DB, Kriska J, Tureckova J. Ischemia-Triggered Glutamate Excitotoxicity from the Perspective of Glial Cells. Front. Cell. Neurosci.2020;14(51). Go to original source... Go to PubMed...
    27. Bridges RJ, Natale NR, Patel SA. System xc-cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. British journal of pharmacology. 2015;165(1):20-34. Go to original source... Go to PubMed...
    28. Alleva C, Machtens JP, Kortzak D, et al. Molecular Basis of Coupled Transport and Anion Conduction in Excitatory Amino Acid Transporters. Neurochemical Research. 2021;46(2):1-14. Go to original source... Go to PubMed...
    29. Gonçalves-Ribeiro J, Pina CC, Sebastião AM, et al. Glutamate transporters in hippocampus: not just prevention of excitotoxicity. Frontiers in cellular neuroscience. 2019;(13):357. Go to original source...
    30. Hubbard JA, Binder DK. Glutamate Metabolism. Astrocytes and Epilepsy Book. Chapter 9. 2016; 97-224. Go to original source...
    31. Fontana ACK. Current approaches to enhance glutamate transporter function and expression. J. Neurochem. 2015;134(6):982-1007. Go to original source... Go to PubMed...
    32. Martineau M, Guzman RE, Fahlke C. VGLUT1 functions as a glutamate/proton exchanger with chloride channel activity in hippocampal glutamatergic synapses. Nature Communications.2017;8(1):2279. Go to original source... Go to PubMed...
    33. El Mestikawy S, Wallén-Mackenzie Å, Fortin GM, et al. From glutamate co-release to vesicular synergy: vesicular glutamate transporters. Nature Reviews Neuroscience. 2011;12(4):204-216. Go to original source... Go to PubMed...
    34. Koppula P, Zhang Y, Zhuang L, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018;38(1):12. Go to original source... Go to PubMed...
    35. Liu L, Liu R, Liu Y, et al. Cystine-glutamate antiporter xCT as a therapeutic target for cancer. Cell Biochem Function. 2021;39(2):159-345. Go to original source... Go to PubMed...
    36. Matuz-Mares D, Riveros-Rosas H, Vilchis-Landeros MM. Glutathione Participation in the Prevention of Cardiovascular Diseases. Antioxidants 2021;10(1220):1-19. Go to original source... Go to PubMed...
    37. Smaga I, Frankowska M, Filip M. N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research. Pharmacological Reports. 2021;73(5):1205-1219. Go to original source... Go to PubMed...
    38. Sari Y, Smith KD, Ali PK. Upregulation of GLT1 attenuates cue-induced reinstatement of cocaine-seeking behavior in rats. Journal of Neuroscience. 2009;29(29):9239-9243. Go to original source... Go to PubMed...
    39. Knackstedt L A, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol. Psychiatry 2010;67(1):81-84. Go to original source... Go to PubMed...
    40. Rao PS, Sari Y. Glutamate transporter 1: target for the treatment of alcohol dependence. Current medicinal chemistry. 2012;19(30):5148-5156. Go to original source... Go to PubMed...
    41. Verma M, Wills Z, Chu CT. Excitatory dendritic mitochondrial calcium toxicity: implications for Parkinson's and other neurodegenerative diseases. Front. Neurosci. 2018;12:523. Go to original source... Go to PubMed...
    42. GParkin GM, Udawela M, AGibbons A. Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disorders. World J Psychiatry. 2018;8(2):51-63. Go to original source... Go to PubMed...
    43. Anna R. Malik AR, Willnow TE. Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System. Int. J. Mol. Sci. 2019;20(22):5671. Go to original source... Go to PubMed...
    44. Sari Y, Sreemantula SN, Lee MR, et al. Ceftriaxone treatment affects the levels of GLT1 and ENT1 as well as ethanol intake in alcohol-preferring rats. Journal of Molecular Neuroscience. 2013;51(3):779-787. Go to original source... Go to PubMed...
    45. Kryger R, Wilce PA. The effects of alcoholism on the human basolateral amygdala. Neuroscience. 2010;167(2):361-371. Go to original source... Go to PubMed...
    46. Yahn SL, Watterson LR, Olive MF. Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence. Substance Abuse: Research and Treatment. 2013;7(6):1-12 Go to original source... Go to PubMed...
    47. Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77(2):315-323. Go to original source... Go to PubMed...
    48. Ho AM, Qiu Y, Jia YF, et al. Combined effects of acamprosate and escitalopram on ethanol consumption in mice. Alcohol Clin Exp Res. 2016;40:1531-1539. Go to original source... Go to PubMed...
    49. Sari Y. Commentary: Targeting NMDA Receptor and Serotonin Transporter for the Treatment of Comorbid Alcohol Dependence and Depression. Alcohol Clin Exp Res. 2017;2 (1):1-4. Go to original source... Go to PubMed...
    50. Jose NA, Yadav P, Kapoor A, et al. Comparison between baclofen and topiramate in alcohol dependence: A prospective study. Ind Psychiatry J. 2019;28(1):44-50. Go to original source...
    51. D'Souza MS. Glutamatergic transmission in drug reward: implications for drug addiction. Front. Neurosci. 2015;5(9):404. Go to original source...
    52. Morley KC, Kranzler HR, Luquin N, et al. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials.2018;19(1):443. Go to original source... Go to PubMed...
    53. Baltieri DA, Daro FR, Ribeiro PL, et al. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008; 03(12):2035-2044. Go to original source... Go to PubMed...
    54. Paparrigopoulos T, Tzavellas E. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11(41). Go to original source... Go to PubMed...
    55. Agabio R, Sinclair JM, Addolorato G, et al. Baclofen for the treatment of alcohol use disorder: The Cagliari Statement. Lancet Psychiatry. 2018;5(12):957-960. Go to original source... Go to PubMed...
    56. de Beaurepaire R, Sinclair JMA, Heydtmann M. review article: The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Frontier in psychiatry. 2019;9:(708). Go to original source...
    57. Parmar PM, Solanki VV, Barvaliya MJ, et al. Cephalosporins Associated Pseudomembraneous Colitis in an Elderly Male Patient - A Case Report. Curr Drug Saf. 2017;12(3):205-207. Go to original source... Go to PubMed...
    58. Smaga I, Fierro D, Mesa J, et al. Molecular changes evoked by the beta-lactam antibiotic ceftriaxone across rodent models of substance use disorder and neurological disease. 2020;115:116-130. Go to original source... Go to PubMed...
    59. Das SC, Yamamoto BK, Hristov AM, et al. Ceftriaxone attenuates ethanol drinking and restores extracellular glutamate concentration through normalization of GLT-1 in nucleus accumbens of male alcohol preferring rats. Neuropharmacology. 2015;97:67-74. Go to original source... Go to PubMed...
    60. Xian XH, Gao JX, Qi J. Activation of p38 MAPK participates in the sulbactam-induced cerebral ischemic tolerance mediated by glial glutamate transporter-1 upregulation in rats. Scientifc Reports. 2020;10(20601):1-11. Go to original source... Go to PubMed...
    61. Bajrektarevic D, Nistri A. Ceftriaxone-mediated upregulation of the glutamate transporter GLT-1 contrasts neurotoxicity evoked by kainate in rat organotypic spinal cord cultures. Neurotoxicology .2017;60,34-41. Go to original source... Go to PubMed...
    62. Rao PS, Sari Y. Effectiveness of ceftriaxone treatment in preventing relapse-like drinking behavior following long-term ethanol dependence in P rats. Journal of addiction research & therapy. 2014;5(2).
    63. Qrunfleh AM, Alazizi A, Sari Y. Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior in alcohol-preferring rats. J. Psychopharmacol. 2013;27(6):541-549. Go to original source... Go to PubMed...
    64. Abulseoud OA, Camsari UM, Ruby CL, et al. Attenuation of Ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2. Neuropsychopharmacology.2014;39(7):1674-1684. Go to original source... Go to PubMed...
    65. Cheung MY, Auyeung WK, Li KP. A Rice Immunophilin Homolog, OsFKBP12, Is a Negative Regulator of Both Biotic and Abiotic Stress Responses. Int. J. Mol. Sci. 2020;21(22):8791. Go to original source... Go to PubMed...
    66. Tong M, Jiang Y. FK506-Binding Proteins and Their Diverse Functions. Curr Mol Pharmacol. 2015;9(1):48-65. Go to original source... Go to PubMed...
    67. Sari Y. Role of glutamate transporter 1 in the attenuation of alcohol intake. Front. Neurosci.2014;8(8):200. Go to original source... Go to PubMed...
    68. Sari Y, Sreemantula SN. Neuroimmunophilin gpi-104 reduces ethanol consumption in part through activation of glt1 in alcohol-preferring rats. Neuroscience.2012;227:327-335. Go to original source... Go to PubMed...
    69. Alhaddad H, Kim NT, Althobaiti YS, et al. Effects of MS-153 on chronic ethanol consumption and GLT1 modulation of glutamate levels in male alcohol-preferring rats. Frontiers in behavioral neuroscience.2014;8:366. Go to original source... Go to PubMed...
    70. Fontana AC, Fox DP, Zoubroulis A. Neuroprotective Effects of the Glutamate Transporter Activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) following Traumatic Brain Injury in the Adult Rat. J. Neurotrauma. 2016;33(11):1073-83. Go to original source... Go to PubMed...

    Return to the content